ACOT8 Inhibitors

ACOT8 inhibitors encompass a diverse array of chemical entities that do not directly inhibit the enzymatic activity of ACOT8 but instead modulate the enzyme's function by altering substrate availability, cofactor interaction, or parallel metabolic pathways. These compounds influence lipid metabolism and fatty acid oxidation, which are processes intimately linked with the function of ACOT8. For example, Triacsin C, by inhibiting acyl-CoA synthetase, can reduce the formation of acyl-CoA substrates necessary for ACOT8 activity, thereby indirectly reducing its function. Similarly, Etomoxir, Perhexiline, and the natural compound malonyl-CoA can alter the intracellular concentrations of acyl-CoA or its derivatives, which can indirectly influence the activity of ACOT8 by modulating the enzyme's substrate availability.

These chemicals, classified as indirect ACOT8 inhibitors, are not part of a single chemical class but rather represent a variety of compounds that interact with different aspects of lipid metabolism. Their effects on ACOT8 are a consequence of their primary actions on other targets within the lipid metabolic pathways. These compounds can cause changes in the intracellular concentrations of substrates and products related to the enzymatic reaction catalyzed by ACOT8, which can result in altered enzyme activity. It's important to note that while these compounds influence pathways that ACOT8 is involved in, they do not interact with the enzyme directly. Instead, their inhibition is a secondary effect stemming from their primary metabolic targets.